Jim Kleinburd (Chairman, BOD) manages an investment holding company specializing in early-stage companies, with an emphasis on the Israeli market. He has been active in the innovation scene since 1996. A Wharton School graduate, his background includes helping companies develop strategic plans and following through in implementation of those plans. He has participated as a principal in acquisition, mergers and exits in more than two dozen transactions with a market value of over $200 million.
Irene Jaffe, PhD, (Chief Executive Officer, BOD) has over twenty-five years’ experience in Biomedical R&D projects and innovation. Over the last decade and a half Irene has focused on New Technology Evaluation & Management, specifically in young medical start-ups, Business Development, IP Assessment, Corporate Strategy and Licensing. Irene was appointed DermaFlow CEO in November 2010. Irene holds a Ph.D. degree in Chemistry from the Weizmann Institute of Science, was a postdoctoral fellow at MIT.
Ilya Skoletsky, EEng, (Chief Technology Officer, BOD) has broad experience in the field of electronic measuring techniques across a number of industries. His work includes developing physiological measuring instruments,optical and RF equipment. Ilya holds degrees in Electrical Engineering with a MSc in Information Technology and holds more than 28 US and Russian patents.
Daniel Weiss, MD, EEng, (Chief Medical Officer) has many years clinical product development experience including proficiency in working with FDA matters and clinical trial protocol issues. Daniel, a practicing cardiologist has been a consultant to Fortune 500 companies such as Medtronic, St Jude Medical and Philips Medical Imaging Systems. Daniel has multiple degrees in Electrical Engineering and Computer Science from Princeton University; and a Medical degree from the Mt. Sinai School of Medicine in New York.
Gary Tremblay, (Chief Financial Officer), CPA, CPIM has over 35 years experience in industries ranging from Finance and Capital Markets to Manufacturing and Health Care. Gary was the Chief Financial Officer for the State of Indiana Medicaid program where he was responsible for directing financial management of over $7 billion in annual program expenditures. His expertise in fiscal administration of publicly funded health plans brings DermaFlow the ability to translate market and product strategies into financial projections based on data driven models.
Joe Franchetti brings to Dermaflow almost 40 years of experience in the medical device field, including senior management positions in organisations now part of both the Covidien and Siemens groups. Joe is currently a non-executive Director of a company focusing on non-invasive diagnostic products in addition to offering consultancy service to the medical device industry. Joe Franchetti is a graduate of Wharton Business School.